Theriva Biologics (TOVX) Non-Current Debt (2022 - 2026)
Theriva Biologics (TOVX) posted quarterly Non-Current Debt of $1.6 million for Q1 2026, up 8.11% year-over-year from $1.5 million in Q1 2025, and down 2.69% quarter-over-quarter from $1.7 million in Q4 2025.
Theriva Biologics (TOVX) Non-Current Debt (2022 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Non-Current Debt for 5 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 8.11% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (up 8.11% YoY), while the FY2025 annual figure was $1.7 million, up 1716.3% from the prior year.
- Non-Current Debt slipped to $1.6 million in Q1 2026 per TOVX's latest filing, from $1.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.7 million in Q4 2025 and bottomed at $92000.0 in Q4 2024.
- Historically, Non-Current Debt has averaged $589941.2 across 5 years, with a median of $202000.0 in 2022.
- Annual changes were most pronounced in 2024 — Non-Current Debt plunged 43.21% — and 2025, when it soared 1716.3%.
- Theriva Biologics' Non-Current Debt stood at $221000.0 in 2022, then dropped by 26.7% to $162000.0 in 2023, then slumped by 43.21% to $92000.0 in 2024, then jumped by 1716.3% to $1.7 million in 2025, then slipped by 2.69% to $1.6 million in 2026.
- Business Quant data shows TOVX's Non-Current Debt at $1.6 million in Q1 2026, $1.7 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 8.96 Bn |
| 10 | Theriva Biologics | 10.93 Mn | 10.93 Mn | - | 1.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Mn |
| Mar 31, 2026 | 1.63 Mn |
| Dec 31, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 92,000.00 |
| Sep 30, 2024 | 98,000.00 |
| Jun 30, 2024 | 93,000.00 |
| Mar 31, 2024 | 159,000.00 |
| Dec 31, 2023 | 162,000.00 |
| Sep 30, 2023 | 150,000.00 |
| Jun 30, 2023 | 153,000.00 |
| Mar 31, 2023 | 160,000.00 |
| Dec 31, 2022 | 221,000.00 |
| Sep 30, 2022 | 202,000.00 |
| Jun 30, 2022 | 216,000.00 |
| Mar 31, 2022 | 229,000.00 |